Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment

The Harvard community has made this article openly available. **Please share** how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th>Citation</th>
<th>Truong, Sandy. 2016. Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment. Doctoral dissertation, Harvard Medical School.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:40620266">http://nrs.harvard.edu/urn-3:HUL.InstRepos:40620266</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
Scholarly Report submitted in partial fulfillment of the MD Degree at Harvard Medical School

Date: 15 February 2016

Student Name: Sandy Truong, BA

Scholarly Report Title: Evaluating the utility of baseline cardiac function screening in early-stage breast cancer treatment

Mentor Names and Affiliations:
Ann H. Partridge MD, MPH, Department of Medical Oncology, Dana-Farber Cancer Institute
Evaluating the utility of baseline cardiac function screening in early-stage breast cancer treatment.

Sandy R. Truong, William T. Barry, PhD, Javid J. Moslehi, MD, Emily L. Baker, Erica L. Mayer, MD, MPH, Ann H. Partridge MD, MPH.

Background: Cardiotoxicity can be a complication of anthracycline or trastuzumab-based therapy for breast cancer patients. Screening echocardiogram (ECHO) and radionuclide ventriculogram (RVG) are often performed prior to administration of these agents to evaluate cardiac function. Limited evidence for the clinical utility of these screening tests is available.

Methods: Early-stage breast cancer patients diagnosed from 2006 to 2011 (n=1067) with a baseline ECHO/RVG were identified in a single institution prospective registry. Medical record review was performed to obtain pre- and post-ECHO/RVG treatment plans, baseline ECHO/RVG results, cardiac risk factors, and cardiac events. Patients with cardiac history were excluded. ECHO/RVG abnormalities were defined as ejection fraction (EF) <55%, valvular disease, left ventricular hypertrophy, and diastolic dysfunction. Cardiac events were defined as heart failure, myocardial infarction, arrhythmia, valvular disease, or angina during or following chemotherapy.

Results: Among 600 eligible patients, abnormal ECHO/RVG were observed in 13 (2.2%, 1.2%-3.7%), including 9 with baseline EF <55%. There were no detected changes in treatment plans, although more frequent cardiac monitoring was recommended for 2 patients. There were no significant differences in age, race, menopausal status, smoking history, alcohol use, body mass index, or medical comorbidities between patients with abnormal and normal results. In follow-up (mean 4.0 years, range 0-8.3), 15 patients developed cardiac events (none of whom had had abnormal baseline ECHO/RVG).

Conclusions: Baseline ECHO/RVG in patients without prior cardiac history rarely yields an abnormality that prompts change in planned anthracycline and/or trastuzumab-based treatment. Moreover, few cardiac events developed in this screened population in follow-up.
Contribution

Dr. Ann Partridge identified a research question from her clinical practice and I worked closely with her to design the study: identifying inclusion/exclusion criteria for subjects and data points to collect for each subject. Dr. Javid Moslehi provided input on the cardiac aspects of the study such as defining cardiac events and important cardiac risk factors. I performed the majority of the execution of the study: obtaining institutional registry data, performing chart reviews to identify eligible patients and to collect our data points, and organizing the data in an online database. Emily Baker assisted with creating the online database. William Barry performed the majority of the statistical analyses. I wrote the original draft of the manuscript, created all the figures and tables, and all authors have read and edited the manuscript. It has been accepted for publication at the Oncologist and we are currently awaiting the proofs.
APPENDIX

Evaluating the utility of baseline cardiac function screening in early-stage breast cancer treatment

Sandy R. Truong\textsuperscript{1,2}, William T. Barry, PhD\textsuperscript{1,2}, Javid J. Moslehi, MD\textsuperscript{4,5}, Emily L. Baker\textsuperscript{2}, Erica L. Mayer, MD, MPH\textsuperscript{1,2}, Ann H. Partridge MD, MPH\textsuperscript{1,2,3}

1. Harvard Medical School, 25 Shattuck St, Boston, MA 02115
2. Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215
3. Brigham and Women’s Hospital, 75 Francis St., Boston, MA 02115
4. Vanderbilt University School of Medicine, 303 Light Hall, Nashville, TN 37232
5. Vanderbilt-Ingram Cancer Center, 2220 Pierce Ave, Nashville, TN 37232

Corresponding Author:
Ann H. Partridge, MD, MPH
450 Brookline Ave Boston, MA 02215
Office: 617-632-4587 Fax: 617-632-1930
Ann_Partridge@dfci.harvard.edu

Short Title: Baseline cardiac screening in breast cancer

Keywords: cardiotoxicity, cardiac function, screening, chemotherapy

Funding: This research was financially supported by the Pink Agenda, LIVESTRONG Foundation, and Susan G. Komen Foundation.

Prior Presentation: A portion of this data was previously presented as a poster at the ASCO Annual Meeting in 2014.
ABSTRACT:

**Background:** Cardiotoxicity can be a complication of anthracycline or trastuzumab-based therapy for breast cancer patients. Screening echocardiogram (ECHO) and radionuclide ventriculogram (RVG) are often performed prior to administration of these agents to evaluate cardiac function. Limited evidence for the clinical utility of these screening tests is available.

**Methods:** Early-stage breast cancer patients diagnosed from 2006 to 2011 (n=1067) with a baseline ECHO/RVG were identified in a single institution prospective registry. Medical record review was performed to obtain pre- and post-ECHO/RVG treatment plans, baseline ECHO/RVG results, cardiac risk factors, and cardiac events. Patients with cardiac history were excluded. ECHO/RVG abnormalities were defined as ejection fraction (EF) <55%, valvular disease, left ventricular hypertrophy, and diastolic dysfunction. Cardiac events were defined as heart failure, myocardial infarction, arrhythmia, valvular disease, or angina during or following chemotherapy.

**Results:** Among 600 eligible patients, abnormal ECHO/RVG were observed in 13 (2.2%, 1.2%-3.7%), including 9 with baseline EF <55%. There were no detected changes in treatment plans, although more frequent cardiac monitoring was recommended for 2 patients. There were no significant differences in age, race, menopausal status, smoking history, alcohol use, body mass index, or medical comorbidities between patients with abnormal and normal results. In follow-up (mean 4.0 years, range 0-8.3), 15 patients developed cardiac events (none of whom had had abnormal baseline ECHO/RVG).

**Conclusions:** Baseline ECHO/RVG in patients without prior cardiac history rarely yields an abnormality that prompts change in planned anthracycline and/or trastuzumab-based treatment. Moreover, few cardiac events developed in this screened population in follow-up.
Implications for practice:

Baseline cardiac function screening with echocardiograms or radionuclide ventriculograms are frequently performed prior to administration of anthracycline- or trastuzumab-based chemotherapy in breast cancer patients due to the relatively low cost and risk to patients and the concern for potential cardiotoxicity. However, at a population level, these tests can take up time and can add up to significant costs for both patients and the healthcare system. This study finds that in patients with no history of cardiac disease, baseline cardiac function screening rarely identifies abnormalities that change treatment plans. Moreover, few cardiac events develop in an average of 4 years of follow-up, none in patients who had had abnormal baseline cardiac function screening results. This suggests that baseline cardiac function screening may have limited utility in chemotherapy planning in young breast cancer patients with no history of cardiac disease.
INTRODUCTION

Anthracyclines and trastuzumab are two very effective systemic therapy agents widely used to treat breast cancer. However, they are associated with risk of adverse cardiovascular complications including cardiac dysfunction and heart failure.\textsuperscript{1-6} Baseline cardiac screening may help avoid cardiotoxicity by detecting pre-existing cardiac conditions, resulting in more frequent cardiac monitoring, administration of cardioprotective medications, and/or modification of planned cancer therapy. Therefore, the American College of Cardiology (ACC), American Heart Association (AHA), and American Society of Nuclear Cardiology suggest that patients be screened for pre-existing cardiac conditions prior to potentially cardiotoxic chemotherapy.\textsuperscript{7}

Echocardiograms (ECHOs) and radionuclide ventriculograms (RVGs, also known as multi-gated acquisition, MUGA, scans) both provide a quantitative measure of cardiac function, the left ventricular ejection fraction (LVEF). Because of the noninvasive nature and broad availability of these exams, they are widely utilized for cardiac screening prior to chemotherapy.\textsuperscript{3} Studies have estimated that between 60\% and 80\% of patients receive baseline cardiac evaluation with RVGs prior to chemotherapy, suggesting variation in implementation of the ACC and AHA recommendation.\textsuperscript{8,9}

Limited prior research suggests that ECHOs and RVGs infrequently reveal clinically significant results that affect oncology treatment plans in this population.\textsuperscript{8-11} In one study of 198 adults, RVGs were conducted in 80\% of breast cancer patients undergoing adjuvant chemotherapy, with only 2.5\% of RVGs indicating cardiac abnormalities, all in smokers.\textsuperscript{9} Baseline ECHO results and potential effects of screening on treatment planning in patients undergoing trastuzumab therapy
have not yet been studied. In addition, a significant portion of patients may have neither cardiac symptoms nor underlying cardiac disease; the utility of baseline cardiac function testing in these patients is unclear. In an effort to understand the utility of baseline cardiac function testing, we conducted a study of women who underwent baseline cardiac screening prior to adjuvant chemotherapy for breast cancer at our institution from 2006 to 2011 to determine how often abnormal ECHO or RVG results changed initial treatment plans, and whether abnormal screening tests were associated with cardiac events during and after chemotherapy.

MATERIALS AND METHODS
We conducted a retrospective analysis of a prospectively collected cohort of newly diagnosed early-stage (stages I-III) female breast cancer patients cared for at Dana-Farber Cancer Institute (DFCI) from 2006 to 2011. A total of 2871 early-stage patients with newly diagnosed breast cancer were identified from the registry, of which 1804 did not receive any cardiac screening, for reasons including they were not planning to receive cardiotoxic or any chemotherapy or the likelihood of baseline cardiac dysfunction was felt to be very low by the provider for any number of reasons such as age, no medical comorbidities, no alcohol or tobacco use, etc. We then reviewed medical record documentation to determine patients’ pre-cardiac screening treatment recommendations, cardiac screening results, and post-cardiac screening treatment recommendations as well as treatment received and subsequent cardiac events. Among the remaining 1067 patients with cardiac screening, 294 had electrocardiograms (EKGs) and no available ECHO or RVG, and were excluded from our analysis. Patients were further excluded from our analysis for the following reasons: a) diagnosis outside of timeframe (n = 2), b) previous history of chemotherapy (n = 9), c) previous history of radiation therapy (n = 15), d)
known cardiac history, defined as diagnosis of myocardial infarction cardiomyopathy, or congestive heart failure (CHF) in institutional registry or medical record review (n = 32), since history of chemotherapy, radiation therapy, and cardiac disease are indications for cardiac function assessment and no longer for screening; e) history of prior cardiac imaging with available results, as these results can influence treatment planning (n = 78), f) no chemotherapy ever indicated in initial treatment discussions so cardiac function screening would not be performed (n = 18), and g) no ECHO/RVG results available in our medical record system (n = 26). Of note, 7 patients met multiple exclusion criteria. Six hundred patients met inclusion criteria and were included in this analysis. Medical comorbidities at baseline associated with risk of cardiac disease, such as hypertension, diabetes, and hyperlipidemia, were also extracted from patients’ medication lists at time of diagnosis from the medical record. Other risk factors for cardiac disease such as age, race, menopausal status, smoking history, alcohol use, and BMI were obtained from the institutional registry. Categories for race were determined by the institutional registry, and patients self-classified their race.

Abnormal cardiac screening results were defined in two ways. The primary measure was LVEF, with normal LVEF values defined as 55% or greater and abnormal values defined as <55%. For ECHOs, secondary measures included additional abnormalities: valvular disease (defined as moderate tricuspid, pulmonic, mitral, aortic regurgitation or stenosis), evidence of left ventricular hypertrophy, and diastolic dysfunction (impaired left ventricular relaxation).

We categorized the impact of abnormal values on treatment plans as: no change nor increased monitoring, no change but recommendation for closer monitoring, or change. “No change but
recommendation for closer monitoring” included more frequent ECHOs or RVGs, cardiac management with medications, and/or coordination of care with a cardiologist. “Change in treatment plans” included recommendations for no chemotherapy, less cardiotoxic chemotherapy, or changes in cardiac medications prior to chemotherapy. Descriptive statistical analyses were done to compare patients with abnormal results to patients with normal results to identify any potential predictors of abnormal results. Differences in demographics between these two groups were evaluated using Fisher exact tests for categorical factors, and Wilcoxon rank sum tests for continuous factors.

We defined a cardiac event in follow-up as symptomatic heart failure, myocardial infarction, arrhythmia, valvular disease (as defined above), or coronary artery disease and correlated it to cardiac imaging including RVG, ECHO, and EKGs when available. The length of follow-up is defined as the start date of chemotherapy to the date of the last clinic visit or the date of diagnosis of recurrence or metastasis. We excluded follow-up data after recurrence or metastasis because patients often underwent additional chemotherapy.

This study was approved by the DFCI institutional review board, and all patients had previously signed informed consent forms to participate in the institutional registry and medical record review studies.

**RESULTS**

For the original 1067 patients with baseline ECHOs, RVGs, or EKGs identified in the registry, the median age was 56 years (range 25-91 years) (see Figure 1 for study cohort flow diagram).
Among the 600 patients included in the analytic sample, the median age was 48 years (range 23-80). In pre-cardiac screening, 79% of treatment plans included anthracycline, 34% included trastuzumab, and 16% included both. ECHOs were performed in 74 of the 600 patients (12.3%) and RVGs in the remaining 526, as per institutional conventions during the study period. Abnormal ECHO and RVG results were observed in thirteen of the 600 patients (2.2%, 95% confidence interval: 1.2%-3.7%), including ten with baseline LVEF <55%, with the lowest at 50% (Figure 2). The other three patients had atrial or ventricular size or thickness abnormalities on ECHO. Four of these thirteen patients received ECHOs, while the other nine received RVGs.

No changes in treatment plan, such as switching to a less cardiotoxic agent or changes in cardiac medications, were made for any of the thirteen patients. However, two patients were recommended to and received more frequent cardiac function assessment via RVG or ECHO and close follow-up with their provider to evaluate for symptoms of cardiac dysfunction. These two patients were relatively young (ages 39 and 49), never smokers, light alcohol drinkers (<1 drink per week), and postmenopausal due to hysterectomy and oophorectomy. One had a BMI of 18.0, while the other had a BMI of 35.6, which were the extremes of the patients with abnormal cardiac screening results. They developed no cardiac events in follow-up.

Analysis of basic demographics between patients with abnormal versus normal cardiac screening results showed no statistically significant differences (p > 0.05) in age, race, menopausal status, smoking history, alcohol use, BMI, or medical comorbidities including hypertension, diabetes, and hyperlipidemia (Table 1). Given the infrequency of abnormal results, further statistical analysis to determine potential predictors of abnormal results was not pursued.
Of the 600 patients, 546 (91%) completed their course of chemotherapy. 24 patients (3.8%) did not complete anthracyclines or trastuzumab chemotherapy due to toxicity, 17 due to anthracycline toxicity, 11 due to trastuzumab toxicity, with 4 with toxicity to both agents. The remaining 30 patients did not complete chemotherapy due to toxicity to paclitaxel (21, 3.5%), reaction to carboplatin (1, 0.2%), neutropenia (1, 0.2%) disease progression (3, 0.5%), transfer of care to another hospital (1, 0.2%), patient preference (1, 0.2%), and persistent reduction in LVEF (2, 0.3%). Only two patients with abnormal baseline screening did not complete chemotherapy, both due to toxicity to paclitaxel.

All 600 patients were followed for cardiac events with median follow-up of 4.0 years (range 0 to 8.3 years). Sixty-six patients (11%) developed recurrent or metastatic disease. Fifteen patients (2.5%) were found to have cardiac events (Table 2). These included two cases of symptomatic heart failure, nine cases of new arrhythmias such as supraventricular tachycardia and atrial fibrillation, four cases of valvular disease, and one case of angina with coronary artery disease on catheterization. One patient developed heart failure followed by tricuspid regurgitation. As above, the infrequency of abnormal baseline cardiac findings precluded further analysis to identify predictors of cardiac events. Of note, none of the patients with abnormal baseline cardiac results developed cardiac events.

**DISCUSSION**

Baseline cardiac screening is commonly performed to assess for pre-existing cardiac dysfunction in women planning for chemotherapy or trastuzumab therapy. However, detection of
abnormalities is infrequent and has little effect on treatment recommendations or subsequent cardiac events in a population of breast cancer survivors. The results of our analysis call into question the utility of baseline pretreatment cardiac evaluation in women without cardiac history for whom systemic chemotherapy with potentially cardiotoxic agents is planned.

The results of our analysis confirm and expand upon prior research in this area. Sabel et al. conducted a retrospective study of 296 patients with breast cancer, 62 of whom had pre-chemotherapy RVGs, and showed a 6.5% rate of low LVEF (between 49% and 51%, low LVEF defined as ≤51%). No cases were identified in which women were not treated with anthracycline-based chemotherapy due to abnormal baseline RVG scans. The authors concluded that pretreatment RVG scans rarely screened out women considering anthracycline-based chemotherapy. Similarly, Conrad et al. conducted a retrospective study of 197 patients with diffuse large B-cell lymphoma considering anthracycline-based chemotherapy, with 117 undergoing baseline LVEF assessment. Of these 117 patients, median age was 69 years and 50% were male. Asymptomatic left ventricular dysfunction was found in four patients (4%) with LVEF ranging from 41% to 48%. No modifications to treatment strategies were made because of LVEF findings. Additionally, Jeyakumar et al. further confirmed in a population-based study of 238 breast cancer patients that, of the 198 patients who underwent baseline RVG screening, five patients (2.5%) had abnormal LVEF, ranging from 35% to 47%. These findings resulted in change to nonanthracycline-based chemotherapy in three patients and no chemotherapy in one patient. In 2014, Bryant et al. studied 119 patients diagnosed with acute myeloid leukemia, with 71 undergoing baseline LVEF measurements with ECHO or RVG. The average age in this cohort was 61 years with 62% male patients. Only four patients (5.6%) had abnormal values with
none that changed management. With regards to cardiac events in follow-up, Romond et al. found that in 7 years of follow-up in a randomized trial, 4.0% of patients developed cardiac events after receiving anthracyclines and trastuzumab compared to 1.3% in patients receiving anthracyclines only. Risk factors associated with development of CHF include baseline LVEF 50% to 54%, age (2.3% in <50 years, 5.5% in 50-59 years, and 6.1% in ≥60 years), and antihypertensive medications at baseline.\(^{12}\)

Our analysis represents the largest study to assess the utility of baseline cardiac function evaluation in systemic treatment planning for breast cancer patients considering potentially cardiotoxic systemic therapy and is the first to evaluate this among patients planned to receive trastuzumab therapy. Further, our study is the first to show the low risk of subsequent cardiac events in follow-up and the lack of association between prior abnormal cardiac screening and subsequent cardiac events, adding new evidence to reconsider the routine practice of baseline cardiac function screening in this setting.

Our findings should be interpreted in consideration of several potential limitations. Although most of our study data were prospectively collected, our analysis was retrospective and may be subject to biases common to retrospective studies. Subgroup analysis to determine whether a difference exists in threshold to treat with anthracyclines versus trastuzumab could not be performed. Trastuzumab was discussed with many patients at the initial clinic visit because final pathology results were not yet available. However, at the post-cardiac screening visit, when HER2 status was known, HER2 negative patients no longer required trastuzumab and further conversation about this agent did not occur, and this was not considered a change in therapy plan.
based on the baseline cardiac screening. Furthermore, our final study cohort was relatively young with a mean age of 48 years, which may limit the generalizability of our findings to older patient populations even though our study population included patients as old as 80 years. As noted in our results, the average age of our entire cohort was 57, which decreased to 48 after patients were excluded. Thus, patients excluded from analysis due to prior cardiac history, cardiac imaging, chemotherapy or radiation therapy were older on average (mean age of the 467 excluded patients was 68.5 years, with ages ranging from 25 to 91 years). It is also worth noting that the majority of the patients seen at our institution did not have baseline cardiac screening, and only 773 out of 2871 (or 26.9%) underwent baseline ECHO/RVG testing during this time period. Some patients may have had such an early-stage cancer that chemotherapy was not warranted, and some would have been deemed to be very low risk of baseline cardiac dysfunction so baseline ECHO/RVG testing was never performed. Moreover, some patients were enrolled in clinical trials that required baseline cardiac assessment, which may not otherwise have been performed. In addition, though our analysis provides the first evaluation of how the patients fared from a cardiac standpoint following cancer treatment, time to last follow-up was limited for some, and identification of cardiac event relied on single institution medical record review. Finally, the majority of screening cardiac evaluations done were RVGs due to institutional convention at the time, and results may have been different had imaging been predominantly ECHOs.

CONCLUSION

The results of this study suggest that baseline cardiac function screening has limited impact in clinical decision-making in young breast cancer patients without pre-existing cardiac history or
other prior exposures considering anthracycline-based and/or trastuzumab chemotherapy. Thus, thorough clinical assessment for cardiac history, symptoms, risk factors, and physical exam should be performed in all patients. However, considering the low rates of cardiac events in follow-up of patients receiving primarily low risk chemotherapy combinations, omitting baseline screening in young patients (<50 years) with an otherwise negative cardiac history may be prudent in the future. Baseline screening can be considered on case-by-case basis in patients with cardiac risk factors such as hypertension, diabetes, hyperlipidemia, high BMI, alcohol or tobacco use, though these factors were not associated with abnormal cardiac screening results in our study. However, further evaluation of the utility of baseline testing during follow-up care and particularly, in older breast cancer patients who are generally at greater risk of cardiac problems is warranted.

COMPETING INTERESTS

The authors declare that they have no competing interests relevant to this study.

ACKNOWLEDGEMENTS

This research was financially supported by the Pink Agenda, LIVESTRONG Foundation, and Susan G. Komen Foundation. These funding organizations had no involvement in the design and conduct of the study.

REFERENCES


Figure and Table Legends

Figure 1. Study cohort
A total of 2871 with newly diagnosed early-stage breast cancer patients were identified from the DFCI Institutional Registry. Of these patients, 1804 had no cardiac screening performed and 294 only had EKGs. Of the remaining 773 patients, 173 patients did not meet eligibility criteria for the above reasons. Seven patients met multiple exclusion criteria.

Figure 2. Impact of cardiac function screening on treatment decision-making
Abnormal results were observed in 13 (2.17%, 1.2%-3.7%) of 600 patients. Of these abnormal results, none led to changes in treatment decisions (e.g., switching to a less cardiotoxic agent), though 2 patients (15.4%, 1.9%-45.5%) received increased monitoring of cardiac function throughout and after treatment.

Table 1. Cohort Characteristics
There were no statistically significant differences (p > 0.05) between the patients with abnormal and normal cardiac screening results. Of note, some patients may have multiple comorbidities while others have no comorbidities so percentages do not add up to 100 and are solely the proportion of patients in that group with that particular comorbidity.

Table 2. Cardiac events observed in follow-up.
Sixteen cardiac events were identified during follow-up. Of note, one patient had two cardiac events that were diagnosed at different times.
Figure and Table Legends

Figure 1. Study cohort
A total of 2871 with newly diagnosed early-stage breast cancer patients were identified from the DFCI Institutional Registry. Of these patients, 1804 had no cardiac screening performed and 294 only had EKGs. Of the remaining 773 patients, 173 patients did not meet eligibility criteria for the above reasons. Seven patients met multiple exclusion criteria.

Figure 2. Impact of cardiac function screening on treatment decision-making
Abnormal results were observed in 13 (2.17%, 1.2%-3.7%) of 600 patients. Of these abnormal results, none led to changes in treatment decisions (e.g., switching to a less cardiotoxic agent), though 2 patients (15.4%, 1.9%-45.5%) received increased monitoring of cardiac function throughout and after treatment.

Table 1. Cohort Characteristics
There were no statistically significant differences (p > 0.05) between the patients with abnormal and normal cardiac screening results. Of note, some patients may have multiple comorbidities while others have no comorbidities so percentages do not add up to 100 and are solely the proportion of patients in that group with that particular comorbidity.

Table 2. Cardiac events observed in follow-up.
Sixteen cardiac events were identified during follow-up. Of note, one patient had two cardiac events that were diagnosed at different times.
**DFCI Registry:**
Patients with baseline pre-cardiac screening treatment recommendations, cardiac screening results, and post-cardiac screening treatment
n = 1067

---

**Did not meet eligibility criteria**

n = 467

- a) Diagnosis outside of time frame 2006-2012 (n = 2)
- b) History of chemotherapy (n = 7)
- c) History of radiation therapy (n = 13)
- d) Known cardiac history (n = 29)
- e) History of cardiac imaging with available results (n = 16)
- f) No pre-chemotherapy cardiac screening (n = 378)
- g) No chemotherapy ever indicated in treatment discussions (n = 15)
- h) Patients meeting multiple exclusion criteria (n = 7)

---

**Study cohort**

n = 600

**Abnormal cardiac screening results**

n = 13

- Treatment change n = 0

**Normal cardiac screening results**

n = 587

- Increased monitoring n = 2
- No treatment change nor increased monitoring n = 11

---

**Figure 1.**

**Figure 2.**
Table 1. Cohort Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Patients with normal results (n = 587)</th>
<th>Patients with abnormal results (n = 13)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td>Mean 48.76 (Range 23-80)</td>
<td>Mean 47.30 (Range 34-75)</td>
<td>0.33</td>
</tr>
<tr>
<td><strong>Race/ethnicity</strong></td>
<td></td>
<td></td>
<td>0.68</td>
</tr>
<tr>
<td>White</td>
<td>528 (90)</td>
<td>12 (92)</td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>15 (3)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Hispanic/Latina</td>
<td>14 (2)</td>
<td>1 (8)</td>
<td></td>
</tr>
<tr>
<td>Black/African-American</td>
<td>13 (2)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Other/Unknown</td>
<td>17 (3)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>Menopausal status</strong></td>
<td></td>
<td></td>
<td>0.78</td>
</tr>
<tr>
<td>Premenopausal</td>
<td>317 (54)</td>
<td>7 (54)</td>
<td></td>
</tr>
<tr>
<td>Postmenopausal</td>
<td>224 (41)</td>
<td>6 (46)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>60 (10)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>Smoking</strong></td>
<td></td>
<td></td>
<td>0.16</td>
</tr>
<tr>
<td>Current</td>
<td>34 (6)</td>
<td>2 (15)</td>
<td></td>
</tr>
<tr>
<td>Former</td>
<td>287 (49)</td>
<td>8 (62)</td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>207 (35)</td>
<td>2 (15)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>59 (10)</td>
<td>1 (8)</td>
<td></td>
</tr>
<tr>
<td><strong>Alcohol use</strong></td>
<td></td>
<td></td>
<td>0.85</td>
</tr>
<tr>
<td>Current</td>
<td>372 (63)</td>
<td>9 (69)</td>
<td></td>
</tr>
<tr>
<td>Former</td>
<td>66 (11)</td>
<td>1 (8)</td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>76 (13)</td>
<td>2 (15)</td>
<td></td>
</tr>
<tr>
<td>Comorbidities</td>
<td>Patients (n = 600)</td>
<td>Time to Event (months)</td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>--------------------</td>
<td>------------------------</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>81 (14)</td>
<td>2 (15)</td>
<td></td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>51 (9)</td>
<td>1 (8)</td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>16 (3)</td>
<td>1 (8)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: Body Mass Index (BMI)

**Table 2. Cardiac events observed in follow-up.**

<table>
<thead>
<tr>
<th>Event</th>
<th>Patients (n = 600)</th>
<th>Time to Event (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptomatic Heart Failure</td>
<td>2 (0.33)</td>
<td>34.6, 53.5</td>
</tr>
<tr>
<td>Arrhythmia</td>
<td>9 (1.5)</td>
<td>0.4, 4.6, 9.8, 31.9, 39.2, 36.8, 37, 41.6, 86.6</td>
</tr>
<tr>
<td>Valvular Disease</td>
<td>4 (0.67)</td>
<td>3.2, 8.4, 9.3, 68.1</td>
</tr>
<tr>
<td>Angina</td>
<td>1 (0.17)</td>
<td>71.1</td>
</tr>
</tbody>
</table>